MPM Tries Again To Spur Early-Stage Asian Biotech Investments
This article was originally published in PharmAsia News
Executive Summary
Even though its initial early-stage investment in an Asian biotech seven years ago has seen few copies, MPM Capital of the United States is trying again. The company has invested $20 million in Sai Advantium Pharma, a contract research outfit in India. MPM had hoped to spur investments in Asian biotechs in 2001 when it invested $48 million in Taiwan's TaiGen Biotechnology, a small-molecule drug-discovery firm. Only recently did other investment companies, such as OrbiMed Advisors, follow MPM's lead. Early-stage investments in Asia remain a rarity. (Click here for more
You may also be interested in...
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.